Antibacterials - Growth in resistance rates drives niche indications

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-12-20

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The global antibacterial market, valued at $25.5 billion in 2005, is highly mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing, immunosuppression and emerging resistances, especially in the hospital and former niche markets (e.g. MRSA). The community market, however, is facing a value loss following the patent expiries of several blockbusters (e.g. Pfizer's Zithromax) in 2005.


Scope

  • In-depth analysis of the current antibacterial market situation across the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK)
  • Thorough assessment of underlying commercial and clinical influencers shaping the antibacterial market
  • Detailed sales forecasts for key antibacterial classes, molecules and brands in each of the seven major markets
  • Case study analysis of lifecycle management strategies for Zithromax (Pfizer), Rocephin (Roche) and Biaxin (Abbott) and assessment of their success


    • Report Highlights
    In 2005 the global antibacterial market was valued at approximately $25.5 billion with a modest CAGR of 5.1% since 2001. The fastest growing classes were the carbapenems, glycopeptides and others (e.g. Pfizer's Zyvox (linezolid)). The best selling drug was J&J's/Sanofi-Aventis' Levaquin (levofloxacin) with global sales of $2.4 billion.

    Although gram-positive infections such as MRSA have been a key focus over recent years, Datamonitor's opinion leader research revealed new concerns about gram-negative organisms such as acinetobacter, pseudomonas and ESBL producing strains.

    Ageing, immunosuppression and resistances contribute to the rising incidence of severe infections and fuel the growth of the hospital market. In contrast, the community market is facing a value loss resulting from the patent expiries of blockbusters such as Zithromax (azithromycin) and the incursion of cheap generics.


    Reasons to Purchase

  • Review the clinical and commercial factors driving new product decisions in antibacterials, and the opportunities and threats facing the market
  • Gain insight into future trends and lifecycle management strategies through a detailed market forecast and real case study analyses
  • Understand where concerns, unmet needs and future opportunities lie by learning about the views of key antibacterial opinion leaders.

    • Table of Contents

    Other users found this report page using the following search terms: bacterial antibiotic antibacterial resistance mrsa pyostacine resistance market antibacterials indications targocid zithromax meiact patent price

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.